WET AGE-RELATED MACULAR DEGENERATION
Clinical trials for WET AGE-RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new WET AGE-RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for WET AGE-RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
One-Shot gene therapy aims to free patients from monthly eye injections
Disease control Recruiting nowThis study is testing a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (wet AMD), a leading cause of vision loss. The goal is to see if this single treatment can help patients maintain their vision while drastically reducing or eliminati…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 04, 2026 05:22 UTC
-
One shot could replace years of eye injections for vision loss
Disease control Recruiting nowThis study is testing a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (wet AMD), a leading cause of vision loss. The goal is to see if this single treatment can help the eye produce its own medicine, reducing or eliminating the need for…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Apr 04, 2026 05:21 UTC
-
Could a common pill be the missing piece for stubborn eye disease?
Disease control Recruiting nowThis study is testing if adding a low-dose oral antibiotic (doxycycline) helps patients with wet age-related macular degeneration (AMD) who still have fluid in their eye despite regular anti-VEGF injections. Fifty participants who are 'incomplete responders' to standard treatment…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: University of Iowa • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
Gene test could match eye patients to best drug, save vision
Disease control Recruiting nowThis study aims to see if a person's genes can predict which of two common eye injections works better for treating wet age-related macular degeneration (AMD), a leading cause of vision loss. It will follow 630 patients for 3 years, comparing the standard drug ranibizumab with th…
Matched conditions: WET AGE-RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Parc de Salut Mar • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC